2022
Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study
Rodriguez-Vida A, Maroto P, Font A, Martin C, Mellado B, Corbera A, Orrillo M, Reig O, Querol R, Rios-Hoyo A, Cano L, Alonso J, Martinez G, Galtes S, Taus A, Martinez-Garcia M, Juanpere N, Juan O, Bellmunt J. Safety and efficacy of avelumab plus carboplatin in patients with metastatic castration-resistant prostate cancer in an open-label Phase Ib study. British Journal Of Cancer 2022, 128: 21-29. PMID: 36289372, PMCID: PMC9814154, DOI: 10.1038/s41416-022-01991-4.Peer-Reviewed Original ResearchConceptsProgression-free survivalPhase Ib studyDNA damage repairOverall survivalSafety profileMedian radiographic progression-free survivalMetastatic castration-resistant prostate cancerOpen-label phase Ib studyIb studyDNA damage repair alterationsRadiographic progression-free survivalPD-1/PD-L1 inhibitorsCastration-resistant prostate cancerTreatment-related adverse eventsMedian response durationAndrogen receptor inhibitorsMedian OSSipuleucel-TProlonged OSPretreated populationSurvival benefitPrimary endpointProstate cancerSecondary endpointsAndrogen receptor
2020
Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage
Conde-Estévez D, Monge-Escartín I, Ríos-Hoyo A, Monzonis X, Echeverría-Esnal D, Moliner L, Duran-Jordà X, Taus Á, Arriola E. Prognostic factors and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer treated with immune checkpoint blockage. Journal Of Chemotherapy 2020, 33: 32-39. PMID: 33267748, DOI: 10.1080/1120009x.2020.1849488.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAntineoplastic Agents, ImmunologicalBody Mass IndexCarcinoma, Non-Small-Cell LungFemaleHospitals, UniversityHumansImmune Checkpoint InhibitorsLung NeoplasmsMaleMiddle AgedPrognosisProgression-Free SurvivalProportional Hazards ModelsRetrospective StudiesSex FactorsSocioeconomic FactorsConceptsImmune-related adverse eventsImmune checkpoint inhibitorsNon-small-cell lung cancerAdverse eventsCharacteristics of immune-related adverse eventsDevelopment of immune-related adverse eventsNSCLC patients treated with immune checkpoint inhibitorsPatients treated with immune checkpoint inhibitorsImmune-related adverse events occurrenceTreated with immune checkpoint inhibitorsImmune checkpoint blockageTreated with nivolumabSecond-line settingThirty-one patientsAssociated with improved patient outcomesCheckpoint inhibitorsMedian OSPrognostic factorsImprove patient outcomesGrade 3Lung cancerPatientsPatient outcomesThirty-oneMonths